A mutation in protein kinase C-gamma alters SNC neuron morphology and decreases synaptic vesicles in dopaminergic striatal terminals in the AS/AGU rat


A spontaneous mutation in the Albino Swiss (AS) rat has been shown to be a single point mutation (agu) in the gene coding for the gamma isoform of protein kinase C (PKC-γ). The characteristics of the mutant include movement disorders, a failure to release dopamine in the striatum and elevations of molecules such as parkin and ubiquitin in the substantia nigra pars compacta (SNC). This present study examined SNC cell bodies and dopaminergic synaptic terminals within the caudate-putamen. Cell volume and nuclear volume were reduced in the AS/AGU mutant compared to the AS control, but the volume fractions of mitochondria and rough endoplasmic reticulum were significantly higher. No Lewy bodies were present in the mutant, although microglia were found adjacent to some SNC cells. Dopaminergic terminals were identified in the caudate-putamen by electron microscopy with low-glutaraldehyde fixation and immunohistochemistry for tyrosine hydroxylase using immuno-gold visualisation. AS/AGU mutant rats had less than half of the synaptic vesicles of AS controls; this was not only true of “readily-releasable” zones adjacent to the synaptic cleft but also “storage pool” zones. The findings support the hypothesis that the initial bar to dopamine availability in the striatum is the reduced release, with nigral cell death being a later phenomenon.


Share and Cite:

Al-Kushi, A. , Russell, D. and Payne, A. (2013) A mutation in protein kinase C-gamma alters SNC neuron morphology and decreases synaptic vesicles in dopaminergic striatal terminals in the AS/AGU rat. Journal of Biomedical Science and Engineering, 6, 1129-1136. doi: 10.4236/jbise.2013.612141.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Salminen, A., Kaarniranta, K., Haapsalo, A., Soininen, H. and Hiltunen, M. (2011) AMP-activated protein kinase: A potential player in Alzheimer’s disease. Journal of Neurochemistry, 118, 460-474.
[2] Wang, G., Pan, J. and Chen, S.-D. (2012) Kinases and kinase signalling pathways: Potential therapeutic targets in Parkinson’s disease. Progress in Neurobiology, 98, 207-221.
[3] Pascale, A., Amadio, M., Govoni, S. and Battaini, F. (2007) The aging brain, a key target for the future: The protein kinase C involvement. Pharmaceutical Research, 55, 560-569. http://dx.doi.org/10.1016/j.phrs.2007.04.013
[4] Craig, N.J., Duran Alonso, M.B., Hawker, K.L., Shiels, P., Glencorse, T.A., Campbell, J.M., Bennett, N.K., Canham, M., Donald, D., Gardiner, M., Gilmore, D.P., MacDonald, R.J., Maitland, K., McCallion, A.S., Russell, D., Payne, A.P., Sutcliffe, R.G. and Davies, R.W. (2001) A candidate gene for human neurodegenerative disorders: A rat PKC gamma mutation causes a Parkinsonian syndrome. Nature Neuroscience, 4, 1061-1062.
[5] Clarke, D.J. and Payne, A.P. (1994) Neuroanatomical characterization of a new mutant rat with dopamine depletion in the substantia nigra. European Journal of Neuroscience, 6, 885-888.
[6] Payne, A.P., Sutcliffe, R.G., Campbell, J.M., Favor, G., Russell, D., Bennett, N.K., Clarke, D.J., Branton, R., Davies, R.W., Simpson, E., Tsang, C. and Baxendale, R.H. (1998) Disordered locomotion in the AS/AGU mutant rat and the effects of L-DOPA or fetal midbrain grafts. Movement Disorders, 13, 832-834.
[7] Campbell, J.M., Gilmore, D.P., Russell, D., Growney, C.A., Favor, G., Weir, J., Stone, T.W. and Payne, A.P. (1998) Extracellular levels of dopamine and its metabolite 3,4-dihydroxy-phenylacetic acid measured by microdialysis in the corpus striatum of conscious AS/AGU mutant rats. Neuroscience, 85, 323-325.
[8] Al-Fayez, M., Russell, D., Wayne Davies, R., Shiels, P., Baker, P.J. and Payne, A.P. (2005) Deficits in the midbrain raphe nuclei and striatum of the AS/AGU rat, a protein kinase C-y mutant. European Journal of Neuroscience, 22, 2792-2798.
[9] Lam, A.G., Campbell, J.M., Bennett, N.K., Payne, A.P., Davies, R.W., Sutcliffe, R.G. and McCulloch, J. (1998) Local cerebral glucose utilization in the AS/AGU rat: A mutant with movement disorders. European Journal of Neuroscience, 10, 1963-1967.
[10] Al-Kushi, A.G., Russell, D. and Payne, A.P. (2012) Tyrosine hydroxylase and lewy body molecules immunoreactivity in the SNC neurons of an AS/AGU mutant. World Journal of Neuroscience, 2, 150-155.
[11] Reynolds, E.S. (1963) The use of lead citrate at high pH as an electron-opaque stain in electron microscopy. Journal of Cell Biology, 17, 208-212.
[12] Weibel, E.R. (1979) Stereological methods. Practical methods for biological morphometry. Academic Press, London.
[13] Mayhew, T.M. (1991) The new stereological methods for interpreting functional morphology from slices of cells and organs. Experimental Physiology, 76, 639-665.
[14] Tao-Cheng, J.H. (2006) Activity-related redistribution of presynaptic proteins at the active zone. Neuroscience, 141, 1217-1224.
[15] Schwarting, R.K.W. and Huston, J.P. (1996) The unilateral 6-hydroxydopamine lesion model in behavioural brain research. Analysis of functional deficits, recovery and treatments. Progress in Neurobiology, 50, 275-331.
[16] Flint Beal, M. (2001) Experimental models of Parkinson’s disease. Nature Reviews Neuroscience, 2, 325-332.
[17] Gulley, R.L. and Wood, R.L. (1971) The fine structure of neurons in the rat substantia nigra. Tissue and Cell, 3, 675-690.
[18] Hajdu, F., Hassler, R. and Bak, I.J. (1973) Electron microscopic study of the substantia nigra and the strio-nigral projection in the rat. Zeitschrift fur Zellforschung und Mikroskopische Anatomie, 146, 207-221.
[19] Langston, J.W., Forno, L.S., Rebert, C.S. and Irwin I. (1984) Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine [MPTP] in the squirrel monkey. Brain Research, 292, 390-394.
[20] Choi, W.S., Yoon, S.Y., Oh, T.H., Choi, E.J., O’Malley, K.L. and Oh, Y.J. (1999) Two distinct mechanisms are involved in 6-hydroxydopamineand MPP+-induced dopaminergic neuronal cell death: Role of caspases, ROS and JNK. Journal of Neuroscience Research, 57, 86-94.
[21] Anglade, P., Vyas, S., Javoy-Agid, F., Herrero, M.T., Michel, P.P., Marquez, J., Mouatt-Prigent, A., Ruberg, M., Hirsch, E.C. and Agid, Y. (1997) Apoptosis and autophagy in nigral neurons of patients with Parkinson’s disease. Histology and Histopathology, 12, 25-31.
[22] Marti, M.J., Saura, J., Burke, R.E., Jackson-Lewis, V., Jimenez, A., Bonastre, M. and Tolosa, E. (2002) Striatal 6-hydroxydopamine induces apoptosis of nigral neurons in the adult rat. Brain Research, 958, 185-191.
[23] Tanaka, J., Nakamura, H., Honda, S., Takada, K. and Kato, S. (1988) Neuropathological study on 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine of the crab-eating monkey. Acta Neuropathologica [Berl], 75, 370-376.
[24] Teismann, P., Tieu, K., Cohen, O., Choi, D.K., Wu, D.C., Marks, D., Vila, M., Jackson-Lewis, V. and Przedborski, S. (2003) Pathogenic role of glial cells in Parkinson’s disease. Movement Disorders, 18, 121-129.
[25] Kohutnicka, M., Lewandowska, E., Kurkowska-Jastrzebska, I., Czlonkowski, A. and Czlonkowska, A. (1998) Microglial and astrocytic involvement in a murine model of Parkinson’s disease induced by 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine [MPTP]. Immunopharmacology, 39, 167-180.
[26] Rodrigues, R.W., Gomide, V.C. and Chadi, G. (2001) Astroglial and microglial reaction after a partial nigrostriatal degeneration induced by the striatal injection of different doses of 6-hydroxydopamine. International Journal of Neuroscience, 109, 91-126.
[27] Spillantini, M.G., Crowther, R.A., Jakes, R., Cairns, N.J., Lantos, P.L. and Goedert, M. (1998) Filamentous alphasynuclein inclusions link multiple system atrophy with Parkinson’s disease and dementia with Lewy bodies. Neuroscience Letters, 251, 205-208.
[28] Cookson, M.R. (2005) The biochemistry of Parkinson’s disease. Annual Review of Biochemistry, 74, 29-52.
[29] Gai, W.P., Yuan, H.X., Li, X.Q., Power, J.T., Blumbergs, P.C. and Jensen, P.H. (2000) In situ and in vitro study of colocalization and segregation of alpha-synuclein, ubiquitin, and lipids in Lewy bodies. Experimental Neurology, 166, 324-333. http://dx.doi.org/10.1006/exnr.2000.7527
[30] McNaught, K.S., Perl, D.P., Brownell, A.L. and Olanow, C.W. (2004) Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson’s disease. Annals of Neurology, 56, 149-162.
[31] Forno, L.S., DeLanney, L.E., Irwin, I. and Langston, J.W. (1993) Similarities and differences between MPTP-induced parkinsonsim and Parkinson’s disease. Neuropathologic considerations. Advances in Neurology, 60, 600608.
[32] Dauer, W. and Przedborski, S. (2003) Parkinson’s disease: Mechanisms and models. Neuron, 39, 889-909.
[33] Takahashi, R., Imai, Y., Hattori, N. and Mizuno, Y. (2003) Parkin and endoplasmic reticulum stress. Annals of the New York Academy of Sciences, 991, 101-106.
[34] Ryu, E.J., Harding, H.P., Angelastro, J.M., Vitolo, O.V., Ron, D. and Greene, L.A. (2002) Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson’s disease. Journal of Neuroscience, 22, 10690-10698.
[35] Campbell, J.M., Payne, A.P., Gilmore, D.P., Byrne, J.E., Russell, D., McGadey, J., Clarke, D.J., Davies, R.W. and Sutcliffe, R.G. (1996) Neostriatal dopamine depletion and locomotor abnormalities due to the Albino Swiss rat agu mutation. Neuroscience Letters, 213, 173-176.
[36] Hornykiewicz, O. (1995) Striatal dopamine in dopa-responsive dystonia: Comparison with idiopathic Parkinson’s disease and other dopamine-dependent disorders. In: Segawa, M. and Nomura, Y., Eds., Age-Related Dopamine-Dependent Disorders, Karger, Basel, 101-108.
[37] Leenders, K.L., Salmon, E.P., Tyrrell, P., Perani, D., Brooks, D.J., Sager, H., Jones, T., Marsden, C.D. and Frackowiak, R.S. (1990) The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson’s disease. Archives of Neurology, 47, 1290-1298.
[38] Moratalla, R., Quinn, B., DeLanney, L.E., Irwin, I., Langston, J.W. and Graybiel, A.M. (1992) Differential vulnerability of primate caudate-putamen and striosomematrix dopamine systems to the neurotoxic effects of 1methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proceedings of the National Academy of Sciences of the United States of America, 89, 3859-3863.
[39] Snow, B.J., Vingerhoets, F.J., Langston, J.W., Tetrud, J.W., Sossi, V. and Calne, D.B. (2000) Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism. Journal of Neurology, Neurosurgery & Psychiatry, 68, 313-316.
[40] Cochiolo, J.A., Ehsanian, R. and Bruck, D.K. (2000) Acute ultrastructural effects of MPTP on the nigrostriatal pathway of the C57BL/6 adult mouse: Evidence of compensatory plasticity in nigrostriatal neurons. Journal of Neuroscience Research, 59, 126-135.
[41] Pickel, V.M., Johnson, E., Carson, M. and Chan, J. (1992) Ultrastructure of spared dopamine terminals in caudateputamen nuclei of adult rats neonatally treated with intranigral 6-hydroxydopamine. Brain Research. Developmental Brain Research, 70, 75-86.
[42] Stanic, D., Parish, C.L., Zhu, W.M., Krstew, E.V., Lawrence, A.J., Drago, J., Finkelstein, D.I. and Horne, M.K. (2003) Changes in function and ultrastructure of striatal dopaminergic terminals that regenerate following partial lesions of the SNpc. Journal of Neurochemistry, 86, 329-343. http://dx.doi.org/10.1046/j.1471-4159.2003.01843.x
[43] Chan, J., Aoki, C. and Pickel, V.M. (1990) Optimization of differential immunogold-silver and peroxidase labeling with maintenance of ultrastructure in brain sections before plastic embedding. Journal of Neuroscience Methods, 33, 113-127.
[44] Kosaka, T., Nagatsu, I., Wu, J.Y. and Hama, K. (1986) Use of high concentrations of glutaraldehyde for immunocytochemistry of transmitter-synthesizing enzymes in the central nervous system. Neuroscience, 18, 975-990.
[45] Beier, K. (1992) Light microscopic morphometric analysis of peroxisomes by automatic image analysis: Advantages of immunostaining over the alkaline DAB method. Journal of Histochemistry & Cytochemistry, 40, 115-121.
[46] Mengual, E. and Pickel, V.M. (2002) Ultrastructural immunocytochemical localization of the dopamine D2 receptor and tyrosine hydroxylase in the rat ventral pallidum. Synapse, 43, 151-162.
[47] Pickel, V.M., Beckley, S.C., Joh, T.H. and Reis, D.J. (1981) Ultrastructural immunocytochemical localization of tyrosine hydroxylase in the neostriatum. Brain Research, 225, 373-385.
[48] Descarries, L., Watkins, K.C., Garcia, S., Bosler, O. and Doucet, G. (1996) Dual character, asynaptic and synaptic, of the dopamine innervation in adult rat neostriatum: A quantitative autoradiographic and immunocytochemical analysis. Journal of Comparative Neurology, 375, 167-186.
[49] Kung, L., Force, M., Chute, D.J. and Roberts, R.C. (1998) Immunocytochemical localization of tyrosine hydroxyllase in the human striatum: A postmortem ultrastructural study. Journal of Comparative Neurology, 390, 52-62.
[50] Payne, A.P., Campbell, J.M., Russell, D., Favor, G., Sutcliffe, R.G., Bennett, N.K., Davies, R.W. and Stone, T.W. (2000) The AS/AGU rat: A spontaneous model of disruption and degeneration in the nigrostriatal dopaminergic system. Journal of Anatomy, 196, 629-633.
[51] Hastings, T.G., Lewis, D.A. and Zigmond, M.J. (1996) Reactive dopamine metabolites and neurotoxicity: Implications for Parkinson’s disease. Advances in Experimental Medicine and Biology, 387, 97-106.
[52] Stokes, A.H., Hastings, T.G. and Vrana, K.E. (1999) Cytotoxic and genotoxic potential of dopamine. Journal of Neuroscience Research, 55, 659-665.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.